Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.

A. O. Smith Corporation is rated a Buy with risk/reward attractive as growth and margins are set to accelerate from FY26.

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

The advent of transcatheter mitral valve repair (TMVr) and replacement (TMVR) has marked a revolutionary shift in the management of mitral valve disease, ...

Future Green Irrigation, a Calgary-based irrigation contractor known for structured service processes and certified technical expertise, announced the expansion of its full irrigation services ...

Transcatheter heart valve repair and replacement have reshaped how structural heart disease is treated, and the market is ...

The global, multibillion-dollar transcatheter heart valves market will grow at an 8.4% CAGR over the rest of the 2020s, ...